[{"Assets_0_Q3_USD":1675654000.0,"CommonStockSharesOutstanding_0_Q3_shares":100968096.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-412159000.0,"NetIncomeLoss_1_Q3_USD":-245282000.0,"NetIncomeLoss_3_Q3_USD":-550056000.0,"StockholdersEquity_0_Q3_USD":1478119000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":2069000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":53875000.0,"Ticker":"ALNY","CIK":"1178670","name":"ALNYLAM PHARMACEUTICALS, INC.","OfficialName":"Alnylam Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"19459816074.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181107"}]